Topic: LY379268

Current therapies for Alcohol Use Disorder (AUD) exhibit significant variability in effectiveness, resulting in high relapse rates. Addressing this challenge requires a precision medicine approach incorporating biomarkers responsive to novel treatments. A promising approach involves bioelectronic devices utilising neuroelectric signatures of impaired prefrontal function, a key feature in AUD resulting in diminished inhibitory control over compulsive behaviour and increased vulnerability to relapse. Thus, we reason that event-related potentials and neural oscillations are valuable biomarkers fo

Metabotropic glutamate receptor 2 (mGlu2) is a G protein-coupled receptor expressed in the central nervous system and canonically coupled to Gi/o protein. mGlu2 receptor is the main target of a new generation of antipsychotics which showed unprecedent efficiency on negative and cognitive symptoms of Schizophrenia, which were so far resisting to actual antipsychotics. However, the molecular mechanisms regulating the antipsychotic properties of mGlu2 receptor stimulation remain unclear. In a recent interactomic screen (Philibert et al., Science Advances, 2024), we demonstrated that endogenous mG